⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8172225 | 0.77 | — | — | |
| SCHEMBL11456684 | 0.75 | — | — | |
| SCHEMBL14557426 | 0.73 | CA1 (0.38) | — | |
| SCHEMBL11591249 | 0.73 | — | — | |
| SCHEMBL856357 | 0.73 | MEN1 (0.40) | — | |
| SCHEMBL1937404 | 0.71 | — | — | |
| SCHEMBL991580 | 0.71 | — | — | |
| SCHEMBL2057335 | 0.71 | — | — | |
| SCHEMBL245242 | 0.71 | — | — | |
| SCHEMBL11466973 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4263518-B1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-12570615-B2 | Quinazolinone derivatives | HOFFMANN-LA ROCHE INC. | 2026-03-10 | — | — | US | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12516061-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-01-06 | — | — | US | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250241915-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | PFIZER INC. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12303509-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | PFIZER INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20030162096-A1 | Solvents and novel electrolytic compositions having a large range of stability and high conductivity | ACEP INC. (CA) | 2003-08-28 | — | — | US | disclosed |
| EP-1230224-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-14 | — | — | EP | disclosed |
| US-6296973-B1 | APROTIC POLAR COMPOUNDS AND SOLVENTS | HYDRO - QUEBEC (CA) | 2001-10-02 | — | — | US | disclosed |
| US-20010012591-A1 | Solvents and novel electrolytic compositions having a large range of stability and high conductivity | ACEP INC. (CA) | 2001-08-09 | — | — | US | disclosed |
| WO-2001032633-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
| US-4316021-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| US-4243813-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |